of successful engraftment of a second unrelated BMT without additional conditioning therapy after engraftment failure of the original marrow. A 37-year-old female highly alloimmunized by multiple transfusions received a sex matched HLA-identical unrelated bone marrow transplant for hypoplastic MDS-RA with moderate myelofibrosis. Conditioning Case report consisted of total body irradiation, cyclophosphamide and ATG, GVHD prophylaxis consisted of CsA, MTX
/kg NK cells). The pretransplant leukocyte plantation, additional stem cell transfer from the original cross-match was negative. The post-transplant course was donor has been used successfully for rescue of patients after complicated by moderate mucositis and recurrent febrile engraftment failure. [4] [5] [6] This approach, however, cannot be episodes. Due to the low CD34 count in the graft G-CSF used in unrelated BMT since the donor cannot be easily (480 g) was initiated on day +3 post-BMT. Despite Gcontacted again by the transplant center. We report a case CSF, the patient showed no signs of engraftment at day 21 post-BMT. A bone marrow aspirate was performed on day 18 which showed no signs of hematopoiesis with few lym-by blood smear and DNA-based evaluation of chimerism. day +60 post-first BMT showed an equal proportion of first and second donor hematopoiesis. (Studies of chimerism were performed by amplifying short tandem repeat loci (HumFES, HumFGA, HumVWA) by A bone marrow aspirate was performed at day 72 which showed trilineage regeneration. Quantitative chimerism PCR from DNA, isolated from nucleated cells in the peripheral blood.
9-11 ) status on day +73 post-first BMT showed predominantly second donor hematopoiesis (90%) and declining first Due to the low cell content of the first graft and the high risk of engraftment failure (alloimmunization and moderate donor hematopoiesis (10%), with stable peripheral blood counts ( Figure 2 ). The patient was discharged on day 74 myelofibrosis) the decision was made to activate the second donor and to perform a second BMT on day +25 after two post-BMT. Chimerism status on day 86 post-first BMT showed exclusively second donor hematopoiesis. Despite days of 3.5 mg/kg methylprednisolone on days 23 and 24. The second BMT was performed on day +25 with a sex low oral intake and severe weakness the patient refused hospitalization. She was finally admitted on day 99 with mismatched HLA-A, -B, -DRB1, DQB1 identical donor. In contrast to the first BMT, patient and donor showed a major recurrent fever, severe weakness and anorexia. She died on day 104 despite broad-spectrum antibiotics, and high ABO-mismatch (patient blood group O rh-positive, second donor A 1 rh-positive). The leukocyte cross-match was also caloric parenteral nutrition. Autopsy revealed disseminated toxoplasmosis encephalitis, no signs of acute or chronic negative. The second graft contained 0.77 × 10 Due to the ABO-mismatch plasma an erythrocyte separation was performed. Graft-versus-host prophylaxis after the second graft was with cyclosporin A and prednisolone Discussion only. A bone marrow aspirate and chimerism assessment on the day of the second transplant showed early Rejection or engraftment failure after allogeneic BMT are associated with a high mortality. Alloimmunization, myeloengraftment of the first graft. Despite this, peripheral leukocyte counts remained below 0.5 × 10 9 /l. The first significant fibrosis, low stem cell count of the graft, unrelated BMT and T cell reduction (ATG pretreatment), all present in our increase in peripheral counts was observed on day 32 after the first BMT.
patient, have been associated with an increased risk for engraftment failure. 13 In the presence of rejection or priThe quantitative chimerism status of the peripheral nucleated cells at day 38 post-first BMT showed a predomimary engraftment failure, increased immunosuppression combined with additional stem cell transfer from the orignance of cells from the first donor (75%) and 25% second donor hematopoiesis 13 days after the second transplant.
inal donor have been used. Due to the special status of unrelated donors, this approach cannot be used in graft fail-(Quantitative evaluation of chimerism status of peripheral nucleated cells was performed as published by Scharf et ure after unrelated BMT, leading to the need for a second graft from a different donor, or if available, transfer of autoal 12 (Figure 1) ). The subsequent clinical course was complicated by recurrent fever, an episode of fungal sepsis and a logous stem cells. A second unrelated graft, genetically different from the first graft, combines several risk factors psychotic event. G-CSF was discontinued on day 38 postfirst BMT. Due to continuing requirement for red cell supresulting from the situation of an 'in vivo three-way mixed lymphocyte reaction' which may cause recurrent graft failport and signs of hemosiderosis, erythropoietin 4000 IU/day was initiated on day +52, followed by a sigure or severe acute graft-versus-host disease. The successful engraftment of the second graft in our patient was nificant increase in reticulocytes and a decrease in requirement for red cell support. Quantitative chimerism status on probably mainly due to pretreatment with TBI, cyclophos- 
